HIV Drug Resistance
September 17, 2014
Table of Contents
HIV drugs are designed to keep your viral load under control by preventing the virus from reproducing (or making copies of itself). Sometimes HIV changes, or mutates as it makes copies of itself. These changes may allow the virus to overcome the effects of a drug and keep reproducing. When this happens, we say that HIV has developed resistance to that drug.
Resistance is a major challenge in HIV treatment. Resistance decreases the ability of HIV drugs to control your virus and reduces your treatment options. The best way to prevent resistance is to stick closely (adhere) to your HIV drug regimen. With good adherence, resistance is less likely to develop. This gives your current drugs the best chance of working and will keep more treatment options open to you in the future.
After infecting a CD4 cell (disease-fighting white blood cell), HIV makes many new copies of itself that infect other CD4 cells. This process happens very quickly -- HIV can make billions of new viruses every day. When making new viruses, HIV must copy its genetic information. Copying happens so fast that mistakes are made. These mistakes are called mutations, and they occur randomly.
Some mutations are harmless. They produce weak viruses that cannot infect other CD4 cells. Other mutations can cause big problems -- they allow the virus to reproduce even when it is exposed to certain HIV drugs. If a drug does not work against a mutated virus, that virus will reproduce rapidly. This causes your viral load to go up, and it may be necessary to change drugs to get HIV back under control.
The main reason to use a combination of HIV drugs instead of just one is to block reproduction at several points in HIV's lifecycle. A combination of drugs aimed at several different targets is much better at preventing HIV reproduction than one alone. With less reproduction, viral load is lower, and mutations and resistance are less likely to occur.
Cross-resistance happens when certain mutations cause resistance not just to one drug, but to an entire class of drugs. There are five classes of HIV drugs:
Cross-resistance is more likely to happen in some classes than others. For example, resistance to the NRTI Retrovir also causes resistance to many of the other NRTIs. Resistance to one NNRTI also leads to resistance to most of the other NNRTIs. This may limit your choices when it is time to pick a new combination of HIV drugs.
If you are starting a treatment regimen for the first time, it is important to ask your health care provider about alternatives (a "plan B") in case the current regimen does not work for you. Thinking ahead will help to ensure that you have several good drug choices in the future.
Resistance is common and can be transmitted with the virus. Between five and 20 percent of newly-infected people are infected with strains of the virus that are resistant to at least one HIV medication. This means that some newly-infected people, who have never taken any drugs, already have drug-resistant HIV and have a more limited selection of HIV treatments to choose from. People living with HIV (HIV+) who have already received HIV therapy are even more likely to have resistant virus and fewer drug choices.
The best way to tell if you have drug resistance is to have regular viral load tests. If your HIV drugs are working well to control your virus, your viral load should be "undetectable" -- so low that the test cannot detect any virus in your blood. If you are taking HIV drugs and your viral load does not become undetectable or goes up after you have been taking the drugs for a while, your virus may have developed drug resistance.
If this happens, it is important that you have a drug resistance test. These tests can help you and your health care provider determine if your virus has become resistant to the HIV drugs you are taking and pick new drugs that will work better.
This article was provided by The Well Project. Visit The Well Project's Web site to learn more about their resources and initiatives for women living with HIV. The Well Project shares its content with TheBody.com to ensure all people have access to the highest quality treatment information available. The Well Project receives no advertising revenue from TheBody.com or the advertisers on this site. No advertiser on this site has any editorial input into The Well Project's content.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)